The invention relates to combinations of a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and a double-stranded ribonucleic acid (dsRNA) targeting interleukin-6 (IL-6), and their use in treating cancer.